Shanghai Henlius Biotech, Inc. (2696.HK) HKSE

Currency In HKD

AD

Valuation

Market Cap27.97B
Enterprise Value30.8B
P/E Ratio33.89
PEG Ratio7.36
Price/Sales Ratio3.94
Price/Book Ratio6.47
Enterprise/Revenue4.36
Enterprise/EBITDA26.48

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterJune 30, 2026

Profitability

Profit Margin0.12
Operating Margin0.12
AD

Management Effectiveness

Return On Assets0.07
Return On Equity0.2

Income Statement

Revenue6.67B
Revenue/Share13.65
Gross Profit4.98B
EBITDA1.16B
Net Income805.64M
Diluted EPS1.47

Balance Sheet

Total Cash956.03M
Total Cash/Share1.75
Total Debt3.95B
Total Debt/Equity0.87
Current Ratio0.78
Book Value Per Share8.33

Price History

52-Week Change-20.7
52-Week High87.1
52-Week Low50.25
Moving Average 50 Days63.99
Moving Average 200 Days66.41

Statistics

Average Volume932,417
Shares Outstanding543.5M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A
AD